Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who were 18 years of age or older when they were first diagnosed
- People diagnosed with a specific type of lung cancer called limited-stage small cell lung cancer (covering stages I to III), confirmed by a tissue or cell sample; those with stage I or II must have been considered medically unsuitable for surgery
- People who received chemotherapy followed by radiation therapy as their first treatment, did not have their cancer worsen during that time, and then received at least one dose of a medicine called Durvalumab as a follow-up treatment — continuing until the cancer progressed, side effects became unacceptable, or up to 24 months
- People who started Durvalumab treatment within 3 months of finishing their chemotherapy and radiation therapy
- People who received a type of preventive brain radiation called prophylactic cranial irradiation (PCI) (confirm with trial site)
- People who had a general health status rated at 0, 1, or 2 on the WHO Performance Scale before starting their chemotherapy and radiation therapy (this is a medical measure of how much a person's illness affects their daily activities)
Who may not be able to join:
- People with extensive-stage small cell lung cancer, or a mixed type of lung cancer combining small cell and non-small cell types
- People with active or previously diagnosed autoimmune or inflammatory conditions, or other serious uncontrolled illnesses
- People who still have significant side effects (graded 2 or higher on a standard medical scale) left over from their previous chemotherapy and radiation treatment
- People who received chemotherapy and radiation therapy at the same time (concurrently) for their limited-stage small cell lung cancer
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 18066047640
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incidence of Grade 3 or 4 Adverse Events (AEs) within 6 months of starting Durvalumab [graded by Common Terminology Criteria for Adverse Event (CTCAE) v.5.0]
Can't join this trial?
Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.